Non-Hodgkin Lymphoma Primary Mediastinal Large B-cell Lymphoma New Reference: Pembrolizumab in relapsed or refractory primary mediastinal large B-cell lymphoma Ulas D. Bayraktar, MD 2023-06-07
Breast Cancer New Indication: Randomized Phase II Trial of Endocrine Therapy With or Without Ribociclib After Progression on Cyclin-Dependent Kinase 4/6 Inhibition in Hormone Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Metastatic Breast Cancer (MBC) Ulas D. Bayraktar, MD 2023-06-07
Diffuse Large B Cell Lymphoma Non-Hodgkin Lymphoma New Drug: Glofitamab-gxbm for selected relapsed or refractory large B-cell lymphomas Ulas D. Bayraktar, MD 2023-06-07
Cervical Cancer New Protocol: Tisotumab Vedotin in Combination with Carboplatin, Pembrolizumab, or Bevacizumab in Recurrent or Metastatic Cervical Cancer Ulas D. Bayraktar, MD 2023-06-07
Bladder Cancer New Indication: Perioperative Chemoimmunotherapy With Durvalumab for Muscle-Invasive Urothelial Carcinoma Ulas D. Bayraktar, MD 2023-06-07
Prostate Cancer New Protocol: Abiraterone Acetate With or Without Cabazitaxel in the Treatment of Metastatic Castration-Resistant Prostate Cancer (mCRPC) Ulas D. Bayraktar, MD 2023-06-07
Pancreatic Cancer New Protocol: Nimotuzumab Plus Gemcitabine for K-Ras Wild-Type Locally Advanced or Metastatic Pancreatic Cancer Ulas D. Bayraktar, MD 2023-06-07
GastroEsophageal Cancer New Protocol: First-line regorafenib with nivolumab and chemotherapy in advanced esophageal, gastric, or gastro-esophageal junction cancer Ulas D. Bayraktar, MD 2023-06-07
Non-Small Cell Lung Cancer New Drug: Pralsetinib for non-small cell lung cancer with RET gene fusions Ulas D. Bayraktar, MD 2023-06-07
Multiple Myeloma New Drug: Talquetamab-tgvs for relapsed or refractory multiple myeloma Ulas D. Bayraktar, MD 2023-06-07
